- Hepatitis C Virus patent assignments: patents with HCV in the patent claim
- KEI Policy Brief: Non-Voluntary use of HCV patents in the United States
- SCCR28: Chair’s Conclusions (No recommendations on broadcasting or limitations and exceptions for libraries and archives)
- Gilead in 2013: AbbVie sought to eliminate competition and dominate market for HCV drugs
- KEI asks FTC to investigate Shire decision to abandon efforts to compete in US market for Fabry’s disease treatments
- New UK Parliamentary report on Global TB urges the United Kingdom to explore a WTO Agreement on the Provision of Public Goods
- US Court issues compulsory license for know-how protected as trade secret
- Senators Wyden and Grassley launch investigation of pricing of Sovaldi, treatment for Hepatitis C Virus
- 28 October 2014: WTO Innovation Fair on the margins of WTO TRIPS Council review of the Paragraph 6 system
- IGC28: African Group Statement on Convening a Diplomatic Conference for the Protection of Genetic Resources, TK and folklore
Claire Cassedy did this interview at the KEI offices, following the February 24, 2014 USTR hearing on the Special 301.
Here is the REVISED agenda for the Special 301 hearing on February 24. Public Citizen has been added to the list of witnesses, and USTR now lists the names of the speakers for the various trade associations. Unlike recent years, the level of participation by major trade organizations is significant.
SPECIAL 301 PUBLIC HEARING
February 24, 2014 – 10:00 a.m.
Office of the United States Trade Representative
1724 F Street, NW
Washington, D.C. 20508
The Special 301 Hearing is open to the public. Members of the press are welcome to attend.
TRIPS Council (February 2014) US tables agenda item on IP & Innovation: University Technology PartnershipsSubmitted by thiru on 19. February 2014 - 2:46
The following WTO airgram WTO/AIR/4240/REV.1 (14 February 2014) contains the agenda for the upcoming WTO Council for TRIPS meeting to be held in Geneva from Tuesday, 25 February 2014 to Wednesday, 26 February 2014.
Public Comments by Brian Pomper-Executive Director of the Innovation Alliance and Alliance for Fair Trade with IndiaSubmitted by thiru on 12. February 2014 - 9:34
Brian Arthur Pomper is a partner at the law firm of Akin Gump.
Mr. Pomper formerly served as chief international trade counsel to Senate Finance Committee Chairman Max Baucus (D-MT). In that role, he was responsible for advising Chairman Baucus and other members of the Senate Finance Committee on all aspects of the Committee’s international trade and economic agenda.
Special 301: NFTC puts plain packaging policies of Australia, EU, Thailand, UK, Ireland and New Zealand under the spotlightSubmitted by thiru on 11. February 2014 - 4:21
The National Foreign Trade Council (NFTC) submission (7 February 2014, Docket USTR-2013-0040) to USTR's 2014 Special 301 Review contains a section on plain packaging policies in the context of the protection of trademarks.
The Alliance for Fair Trade with India (AFTI) was created in June 2013, to lobby for "increased action to address the erosion of intellectual property rights ("IPR") in India." According to the group, it is "comprised of organizations representing a range of U.S. industries adversely impacted by India's troubling and frequently discriminatory policies, including manufacturing, agriculture, telecommunications, pharmaceuticals and beyond."
NFTC, a US trade association, asks USTR to sanction China for issuing and enforcing "junk patents" (2014 submission)Submitted by James Love on 9. February 2014 - 16:40
A February 7, 2014 Special 301 submission from the National Foreign Trade Council (NFTC) asks USTR to bring trade sanctions against China for granting and enforcing "junk patents." The NFTC also wants patent enforcement to be strickly a private civil remedy (Contrast to the USTR demands that countries implement linkage between drug registration and patents), and complains about China rules that would require employers to more fairly compensation the Chinese inventors they
Transcript of Bayer CEO Marjin Dekkers quote at the December 3, 2013 FT Event, regarding India compulsory license of NexavarSubmitted by Claire Cassedy on 7. February 2014 - 9:25
On January 21, 2014, Ketaki Gokhale of Bloomberg published a story in Businessweek on disputes over drug patents. The story closed with a rather sinister quote attributed to Bayer CEO Marijn Dekkers, "We did not develop this medicine for Indians.
US International Trade Commission Hearing, "Trade, Investment, and Industrial Policies in India: Effects on the US Economy"Submitted by Claire Cassedy on 6. February 2014 - 15:35
Next week, the United States International Trade Commission (ITC) will hold a two-day hearing on "Trade, Investment, and Industrial Policies in India: Effects on the US Economy." The first session will take place Wednesday, February 12, 2014 at 1:00pm and the second session will convene on Thursday, February 13, 2014 at 9:30am. Both sessions will be held at the ITC in the Main Hearing Room (room 101) at 500 E Street SW, Washington, DC.
Composition of the WIPO Coordination Committee: 83 countries invested with power to nominate the WIPO Director GeneralSubmitted by thiru on 3. February 2014 - 15:15
According to a press release issued by the World Intellectual Property Organization (WIPO) on 6 December 2013, four candidatures for the post of Director General were received before the deadline for nominations (5 PM, 6 December 2013) expired.
The WIPO press release noted that,
The candidates are (in alphabetical order of names of candidates): Mr. Francis Gurry (Australia), Mr. Geoffrey Onyeama (Nigeria), Mr. Jüri Seilenthal (Estonia), and Mr. Alfredo Suescum (Panama).
WIPO norm-setting on IP and genetic resources: will impasse on mandatory disclosure and the nature of instrument be resolved?Submitted by thiru on 3. February 2014 - 9:31
It is crunch time for WIPO's Intergovernmental Committee on Genetic Resources, Traditional Knowledge and Folklore (IGC). The 26th session meets from 3-7 February 2014 in Geneva. This week's session will focus on setting international norms for the protection of genetic resources against misappropriation and resolving two key areas of divergence: 1) the nature of the instrument and 2) the disclosure of origin requirement.
UPDATED- SCP20: Current state of play as countries clash on patents and health (WIPO Standing Committee on the Law of Patents)Submitted by thiru on 31. January 2014 - 8:39
On Friday, 31 January 2014 (6:30 PM Geneva time) the WIPO Standing Committee on the Law of Patents (SCP) resumed in plenary mode to discuss the facilitator's text (Mr. Victor Portelli, Australia) on the future work of this committee including activities on 1) Exceptions and Limitations to Patent Rights, 2) Quality of Patents, including Opposition Systems, 3) Patents and Health, 4 Confidentiality of communications between clients and their patent advisors and 5) Transfer of Technology.
20TH Session of the Standing Committee on the Law of Patents
Statement by Kenya
Agenda Item No. 8: Patents and Health, 28th January 2014
Thank you Mr. Chairman for giving Kenya the floor.
Kenya supports the statement made by Algeria on behalf of the African Group and the proposal put forward by the Group and the DAG.
KEI Intervention at SCP20 on Patents and Health
28 January 2014
Thank you Chair.